Dosing & Uses
Dosage Forms & Strengths
injection solution
- (660mg diatrizoate meglumine/100mg diatrizoate sodium)/1mL
oral/rectal solution
- (660mg diatrizoate meglumine/100mg diatrizoate sodium)/1mL
Aortography
15-40 mL IV or intra-arterially once; may repeat if necessary; not to exceed 160 mL
Contrast Enhancement of CT Brain Imaging
Tumors or non-neoplastic conditions: 1.3 mL/kg IV; not to exceed 125 mL; adequately hydrate patient prior to procedure
Excretory Urography
20 mL IV; may administer 40 mL dose if inadequate visualization occurs
Digital Subraction Angiography
20-60 mL IV; may repeat PRN; hydrate patient adequately prior to procedure
Peripheral Arteriography
Visualization of entire extremity: 20-40 mL
Visualization of lower or uper half of extremity: 10-20 mL
Radiographic Exam of GI Tract Segments
Oral: 30-90 mL
Rectal enema: Dilute 240 mL in 1000 mL tap water
Selective Renal Arteriography
5-10 mL; may repeat PRN; not to exceed 60 mL
Tomography
Dilute 25-77 mL in 1000 mL tap water; administer 240 mL of this solution PO 15-30 min prior to imaging
Dosage Forms & Strengths
injection solution
- (660mg diatrizoate meglumine/100mg diatrizoate sodium)/1mL
oral/rectal solution
- (660mg diatrizoate meglumine/100mg diatrizoate sodium)/1mL
Angiocardiography
Infants and children (<5 years): 10-20 mL
5-10 years: 20-30 mL; not to exceed 100 mL
Aortography
<16 years: Safety & efficacy not established
>16 years: 15-40 mL IV or intra-arterially once; may repeat if necessary; not to exceed 160 mL
Excretory Urography
<6 months: 4 mL
6-12 months: 6 mL
1-2 years: 8 mL
2-5 years: 10 mL
5-7 years: 12 mL
8-10 years: 14 mL
11-15 years: 16 mL
Radiographic Exam of GI Tract Segments
<5 years: 30 mL PO; may dilute 1:1 in a recommended liquid; alternatively may administer enema by diluting in tab water at 1:5 ration
5-10 years: 60 mL PO; may dilute 1:1 in a recommended liquid; alternatively may administer enema by diluting 90 mL in 500 mL tap water
Adverse Effects
Frequency Not Defined
Oral/Rectal
- Diarrhea
- Urticaria
- Dyspnea
- Anaphylaxis
- Hypoxia
- Erythema
- Tachyarrhythmia
- Nausea
- Vomiting
Injection
- Arterial thrombosis, cardiac arrhythmia, brachial plexopathy, chest pain, choking sensation, ECG changes, edema, flushing, hypertension, hypotension, myocardial infarction, venous pain, ventricular fibrillation, chills, headache, pallor, nausea, hypothyroidism, pruritus, skin rash, urticaria, neutropenia, anaphylactoid reaction, burning sensation at injection site, muscle cramps, sneezing, wheezing, conjunctival petechiae, lacrimation
Warnings
Black Box Warnings
Indicated for retrograde pyelography, CT, and angiography
Not for intrathecal use
Contraindications
Hypersensitivity to diatrizoate
Intrathecal use
Myelography
Cautions
Personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents
Iodine sensitivity
Aspiration may occur following oral administration that may result in serious complications
May cause hypovolemia and hypotension due to fluid loss from hypertonic oral/rectal contrast solutions
Serious thromboembolic events including myocardial infarction and stroke reported with intravascular administration
Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after intravascular contrast agent administration; these reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS); reaction severity may increase and time to onset may decrease with repeat administration of contrast agent; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions; avoid administering MD-76R to patients with a history of a severe cutaneous adverse reaction to MD-76R
FDA MedWatch
- March 30, 2022: FDA recommended newborns and children aged ≤3 years have follow-up thyroid monitoring within 3 weeks after receiving iodinated contrast media (ICM) for X-rays and other medical imaging procedures
- Published studies found underactive thyroid and temporary decreases in thyroid hormone levels were uncommon; however, if identified and treated early, future complications may be prevented
- Appropriately monitor for signs and symptoms of hypothyroidism and decreased thyroid hormone levels following ICM exposure; consider evaluating thyroid function within 3 weeks, especially in term and preterm neonates and children with some underlying conditions
- If thyroid dysfunction detected, treat and monitor thyroid function as needed to avoid future complications
- Certain pediatric patients are at increased risk, including newborns or have very low birth weight, prematurity, or presence of cardiac or other conditions (eg, requiring care in neonatal or pediatric ICUs)
- Patients with cardiac conditions may be at greatest risk since they often require high doses of contrast during invasive cardiac procedures
Pregnancy & Lactation
Pregnancy Category: B (oral); C (parenteral)
Lactation: Distributed in milk, use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Contrast enhancement
Pharmacokinetics
Protein binding: Poor binding to albumin
Half-life: 100 min
Excretion: Urine; feces
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Gastrografin oral - | 66-10 % solution |  | |
| Gastrografin oral - | 66-10 % solution |  | |
| MD-Gastroview oral - | 66-10 % solution |  |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
